Αρχική Uncategorized Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for... UncategorizedWorld News Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Από Ogkologos - 25 Αυγούστου, 2026 205 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENZAMET (ANZUP 1304) study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR FDA Approves Capivasertib with Fulvestrant for Breast Cancer 23 Νοεμβρίου, 2023 Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with... 17 Αυγούστου, 2026 Ex-NFL Player Pays For 500 Mammograms To Honor Late Mom Who... 22 Οκτωβρίου, 2019 EMA Recommends Granting a Conditional Marketing Authorisation for Belantamab Mafodotin 29 Ιουλίου, 2020 Φόρτωση περισσοτέρων HOT NEWS ΚΑΡΚΙΝΟΣ ΘΥΡΕΟΕΙΔΟΥΣ How Cancer Survivors Can Overcome Common Challenges of Exercise After Treatment FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell... A new year of expanding research horizons